LIVE CELL APOPTOSIS ASSAY FOR HIGH-THROUGHPUT SCREENING

描述（申请人的摘要）：这项小型企业创新研究 第一阶段项目旨在研究开发新化合物的可行性 能够测量活细胞中细胞凋亡诱导的初始阶段， 组织中如果成功，拟议中的研究将提供所需的突破， 促进有前途的新的细胞凋亡调节药物的发现， 医疗应用。在这个项目的第一阶段，标记基因技术， Inc.建议通过准备新的技术来建立技术的可行性。 半胱天冬酶家族的荧光肽酶底物， 施用至活细胞或组织，所述活细胞或组织已经被诱导 启动细胞凋亡或与疾病有关。这些新的基质和 由此产生的检测系统将提供创新的方法来定量 凋亡诱导和筛选次级药物或 治疗给药。 在第一阶段，将在体外测定新底物的能力， 测量活体细胞中特异性和局部抑制或诱导凋亡 细胞，并以细胞或组织特异性方式进行。在第二阶段， 底物将作为分析工具在体内和在 各种重要的医疗应用。 拟定商业应用： 该项目的成功在以下领域开辟了巨大的商业可能性： 癌症和退行性疾病等增殖性疾病的医疗干预 例如阿尔茨海默氏病，在细胞培养系统中筛选新蛋白质和药物 调节细胞凋亡的功效，以及一般的新肽酶检测策略。 在 此外，它将导致这些领域的许可产品。

DESCRIPTION (Applicant's Abstract): This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of measuring initial stages of apoptosis induction in living cells and tissues. If successful, the proposed research will provide breakthroughs needed to advance the discovery of promising new apoptosis modulating drugs for medical applications. In Phase I of this project, Marker Gene Technologies, Inc. proposes to establish the feasibility of the technology by preparing new fluorogenic peptidase substrates for the Caspase family of enzymes, for administration to living cells or tissues that either have been induced to initiate apoptosis or are of disease interest. These new substrates and the resulting detection systems will provide innovative methods to quantitate apoptosis induction and to screen for the influence of secondary drug or treatment administration. In Phase I, the new substrates will be assayed in vitro for their ability to measure specific and localized inhibition or induction of apoptosis in living cells and to do so in a cell- or tissue-specific manner. In Phase II, the substrates will be further tested as an analytical tool in vivo and in a variety of significant medical applications. PROPOSED COMMERCIAL APPLICATION: The success of this project opens up enormous commercial possibilities in the field of medical intervention in proliferative diseases such as cancer and degenerative diseasess such as Alzheimer's disease, screening of new proteins and drugs in cell-culture systems for efficacy in modulating apoptosis, and general new peptidase detection strategies. In addition, it will lead to licensable products in these areas.